Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo
| Autor: | B. Onteniente, M. Lhuillier, Catherine Widmann, Marc Borsotto, Catherine Heurteaux, M Lazdunski, C. Gandin, Frédéric Brau |
|---|---|
| Přispěvatelé: | Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Institut des cellules souches pour le traitement et l'étude des maladies monogéniques (I-STEM), Université d'Évry-Val-d'Essonne (UEVE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Généthon, Université Nice Sophia Antipolis (1965 - 2019) (UNS) |
| Rok vydání: | 2010 |
| Předmět: |
Male
Time Factors Neurite Neurogenesis medicine.medical_treatment Proliferation Excitotoxicity Glutamic Acid NeuroAid medicine.disease_cause Neuroprotection Brain Ischemia Cell Line Mice 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine medicine Animals Humans Stroke Cells Cultured Cell Proliferation Focal ischemia 030304 developmental biology Cause of death Neurons Pharmacology 0303 health sciences Cell Death business.industry Glutamate receptor Brain Neuroaid medicine.disease 3. Good health Mice Inbred C57BL Disease Models Animal Neuroprotective Agents Treatment Outcome [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] business Neuroscience 030217 neurology & neurosurgery Drugs Chinese Herbal |
| Zdroj: | Oncogene Oncogene, Nature Publishing Group, 2010, 58 (7), pp.987-1001. ⟨10.1016/j.neuropharm.2010.01.001⟩ Oncogene, 2010, 58 (7), pp.987-1001. ⟨10.1016/j.neuropharm.2010.01.001⟩ |
| ISSN: | 0028-3908 0950-9232 1476-5594 |
| DOI: | 10.1016/j.neuropharm.2010.01.001 |
| Popis: | International audience; Although stroke remains a leading cause of death and adult disability, numerous recent failures in clinical stroke trials have led to some pessimism in the field. Interestingly, NeuroAid (MLC601), a traditional medicine, particularly used in China, South East Asia and Middle East has been reported to have beneficial effects in patients, particularly in post-stroke complications. Here, we demonstrate in a rodent model of focal ischemia that NeuroAid II (MLC901) pre- and post-treatments up to 3 h after stroke improve survival, protect the brain from the ischemic injury and drastically decrease functional deficits. MLC601 and MLC901 also prevent neuronal death in an in vitro model of excitotoxicity using primary cultures of cortical neurons exposed to glutamate. In addition, MLC601/MLC901 treatments were shown to induce neurogenesis in rodent and human cells, promote cell proliferation as well as neurite outgrowth and stimulate the development of a dense axonal and dendritic network. MLC601 and MLC901 clearly represent a very interesting strategy for stroke treatment at different stages of the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect